Sequencing Regorafenib After Fruquintinib Improves OS in mCRC
Initial fruquintinib followed by regorafenib extended OS vs the reverse sequence of the agents in patients with metastatic colorectal cancer.
Related Articles
NAPOLI-3 Analysis Exposes Characteristics of Long-Term PDAC Survivors Treated With NALIRIFOX
A post hoc analysis of NAPOLI-3 reveals insights on long-term survivors with pancreatic cancer who received NALIRIFOX.
First-Line Fruquintinib Combo May Offer New Treatment Strategy in ESCC
A fruquintinib regimen appeared safe and effective when used as a frontline treatment in esophageal squamous cell carcinoma.
Ipatasertib Plus Fulvestrant Demonstrates Significant PFS Benefit in ER+/HER2– Metastatic Breast Cancer
Ipatasertib plus fulvestrant extended PFS vs placebo plus fulvestrant in patients with ER-positive/HER2-negative metastatic breast cancer.
Dr Curtis on Cyclophosphamide GVHD Prophylaxis in Matched Donor Transplant
David Curtis, MBBS, PhD, FRACP, FRCPA, discusses the use of post-transplant cyclophosphamide GVHD prophylaxis in matched donor peripheral blood SCT.
D-VRd Retains Its Role as a Potential Standard of Care for Transplant-Ineligible Multiple Myeloma
D-VRd led to deeper and more durable responses that translated into improved PFS vs VRd alone in transplant-ineligible patients with multiple myeloma.
First-Line T-DXd Plus Pertuzumab Yields PFS Benefit in HER2+ Advanced Breast Cancer
Trastuzumab deruxtecan plus pertuzumab produced a statistically significant PFS improvement in frontline HER2-positive advanced breast cancer.
How Firsthand Breast Cancer Experience Shaped a Surgeon’s Mission to Educate Colleagues and Empower Patients: With D. Ross Camidge, MD, PhD; and Liz O’Riordan, FRCS, PhD
D. Ross Camidge, MD, PhD sat down with Liz O’Riordan, FRCS, PhD, who describes herself as a breast surgeon who has had breast cancer.
Optimizing TKI Selection and Sequencing Strategies in Advanced GIST Beyond First-Line Therapy
Experts discuss optimizing TKI selection and sequencing strategies for advanced gastrointestinal stromal tumors (GIST) beyond first-line therapy, focusing on the latest clinical data, molecular characterization,…
Subcutaneous Daratumumab Approaches EU Approval in High-Risk Smoldering Myeloma
The EMA’s CHMP has issued a positive opinion regarding the use of subcutaneous daratumumab in high-risk smoldering myeloma.
Relacorilant/Nab-Paclitaxel Is Associated With Survival Improvement in Platinum-Resistant Ovarian Cancer After Short Platinum-Free Interval
Relacorilant plus nab-paclitaxel improved survival in platinum-resistant ovarian cancer with a primary platinum-free interval of 1 to 6 months.